Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.70−0.43 (-6.03%)
Close on Nov 18, 2026Market cap $359.32MP/E –Yield –
Avalo Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Avalo Therapeutics's pe ratio was 1.2× on Jul 31, 2025, against 330.8× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 1.2× | −39.8 |
| 2018 | Oct 31, 2018 | 41.0× | −278.8 |
| 2017 | Dec 29, 2017 | 319.8× | – |
See a number that looks wrong?